Evidence map›Paper›PMID 38005911›Full record

ReviewViruses2023

The Application of Prodrugs as a Tool to Enhance the Properties of Nucleoside Reverse Transcriptase Inhibitors.

Lívia da Rocha Fernandes, Juliana Romano Lopes, Andressa Francielli Bonjorno, João Lucas Bruno Prates, Cauê Benito Scarim, Jean Leandro Dos Santos

Abstract readReview
In one paragraph

Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Current Trends in Clinical Trials of Prodrugs.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lívia da Rocha FernandesSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil.
Juliana Romano LopesSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil.ORCID 0000-0002-3141-501X
Andressa Francielli BonjornoSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil.ORCID 0000-0002-8666-008X
João Lucas Bruno PratesSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil.
Cauê Benito ScarimSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil.ORCID 0000-0002-2540-6395
Jean Leandro Dos SantosSchool of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil.ORCID 0000-0002-2460-2829

Funding

National Council for Scientific and Technological Development 150653/2022-0Pró-reitoria de Pesquisa - UNESP - Edital 01/2023-PROPe/PROPEG. Edital 01/2023-PROPe/PROPEG.São Paulo Research Foundation 2020/13279-7
6 · The paper itself

Abstract

Antiretroviral Therapy (ART) is an effective treatment for human immunodeficiency virus (HIV) which has transformed the highly lethal disease, acquired immunodeficiency syndrome (AIDS), into a chronic and manageable condition. However, better methods need to be developed for enhancing patient access and adherence to therapy and for improving treatment in the long term to reduce adverse effects. From the perspective of drug discovery, one promising strategy is the development of anti-HIV prodrugs. This approach aims to enhance the efficacy and safety of treatment, promoting the development of more appropriate and convenient systems for patients. In this review, we discussed the use of the prodrug approach for HIV antiviral agents and emphasized nucleoside reverse transcriptase inhibitors. We comprehensively described various strategies that are used to enhance factors such as water solubility, bioavailability, pharmacokinetic parameters, permeability across biological membranes, chemical stability, drug delivery to specific sites/organs, and tolerability. These strategies might help researchers conduct better studies in this field. We also reported successful examples from the primary therapeutic classes while discussing the advantages and limitations. In this review, we highlighted the key trends in the application of the prodrug approach for treating HIV/AIDS.

Indexed as

Acquired Immunodeficiency SyndromeAnti-HIV AgentsHIV InfectionsProdrugsHIVHIV Reverse TranscriptaseHumansNucleosidesReverse Transcriptase InhibitorsAnti-HIV AgentsHIV Reverse TranscriptaseNucleosidesProdrugsReverse Transcriptase InhibitorsAIDScodrugsHIVmedicinal chemistrynew drugsnucleoside reverse transcriptase inhibitors (NRTIs)prodrugs

Identifiers

PMID38005911
PMCPMC10675571

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.